NCT02122185 2026-03-27
Metformin and Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University of Chicago
Phase 2 Completed
Clinical Trials
146 trialsNCT04415944 2026-03-19
HIPEC
Wake Forest University Health Sciences
Phase 2 Completed
NCT06173037 2026-01-07
RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
RemeGen Co., Ltd.
Phase 2 Completed
NCT05613088 2025-10-20
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Bristol-Myers Squibb
Phase 2 Completed
NCT01309230 2025-06-08
A Trial of FANGâ„¢ Vaccine for Participants With Ovarian Cancer
Gradalis, Inc.
Phase 2 Completed
NCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
NCT03093155 2024-05-14
Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab
Yale University
Phase 2 Completed
NCT01439490 2024-05-06
FES-PET to Determine ER-expression in Epithelial Ovarian Cancer
University Medical Center Groningen
Phase 2 Completed
NCT00112957 2023-10-04
Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Ludwig Institute for Cancer Research
Phase 2 Completed
NCT01164995 2023-09-07
M10MKO
The Netherlands Cancer Institute
Phase 2 Completed
NCT00993655 2023-08-28
Intraperitoneal vs Intravenous Chemotherapy Following Neoadjuvant Chemotherapy in Ovarian Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT01891344 2023-06-12
ARIEL2
pharmaand GmbH
Phase 2 Completed
NCT00538031 2023-04-21
Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
City of Hope Medical Center
Phase 2 Completed
NCT02107937 2022-05-04
Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma
Sotio Biotech Inc.
Phase 2 Completed
NCT01551745 2021-10-19
Salvage Ovarian FANGâ„¢ Vaccine + Bevacizumab
Gradalis, Inc.
Phase 2 Completed
NCT01853644 2021-10-12
TIVO
Northwestern University
Phase 2 Completed
NCT01146795 2021-02-09
Neoadjuvant Therapy for Ovarian Cancer
Columbia University
Phase 2 Completed
NCT02022917 2021-01-27
Postoperative Adjuvant Chemotherapy With Bevacizumab and Maintenance Bevacizumab After Neoadjuvant Chemotherapy for Ovarian Cancer
Chang Gung Memorial Hospital
Phase 2 Completed
NCT00227721 2020-12-02
Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT01536743 2020-06-05
A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00030446 2020-04-08
Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT00003892 2020-04-06
ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT00010179 2020-04-06
Lurtotecan Liposome in Treating Patients With Advanced or Recurrent Ovarian Epithelial Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT00003413 2019-10-17
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
University of Maryland, Baltimore
Phase 2 Completed
NCT01666444 2019-09-26
VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Celgene
Phase 2 Completed
NCT00023712 2019-07-30
Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00022659 2019-07-24
Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00025155 2019-07-24
Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT00053365 2019-07-24
Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00113373 2019-07-24
Lapatinib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00429793 2019-07-24
Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00132067 2019-07-23
Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00993616 2019-07-23
Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin
National Cancer Institute (NCI)
Phase 2 Completed
NCT00407758 2019-03-20
Enzastaurin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Completed
NCT00326885 2018-10-17
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
Neovii Biotech
Phase 2 Completed
NCT01669798 2018-10-16
BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer
Duke University
Phase 2 Completed
NCT00030706 2018-09-28
Ixabepilone in Treating Patients With Relapsed and/or Refractory Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
Montefiore Medical Center
Phase 2 Completed
NCT00281632 2018-09-17
A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00278343 2018-08-29
Cediranib Maleate in Treating Patients With Persistent, Recurrent, or Refractory Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02107950 2018-08-15
Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Carcinoma
Sotio Biotech Inc.
Phase 2 Completed
NCT00114166 2018-07-24
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Completed
NCT00699907 2018-07-24
Effect of Flutamide on Biomarkers in Blood and Tissue Samples From Patients at High Risk of Ovarian Cancer
University of Arizona
Phase 2 Completed
NCT00459290 2018-07-18
Mifepristone in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
GOG Foundation
Phase 2 Completed
NCT00569673 2018-07-18
Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer
GOG Foundation
Phase 2 Completed
NCT01764802 2018-05-30
Psychosexual Intervention in Patients With Stage I-III Gynecologic or Breast Cancer
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT00880360 2018-03-27
ONTAK
The University of Texas Health Science Center at San Antonio
Phase 2 Completed
NCT00381888 2017-12-28
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT00610740 2017-12-28
CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT00617188 2017-12-28
Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT01617629 2017-12-08
CAN-003X
Prima BioMed Ltd
Phase 2 Completed